Ixazomib-lenalidomide-dexamethasone in routine clinical practice
In this video publication, the lead author, Prof Hájek, provides a summary of the article ‘Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma’ published in Future Oncology, which looks at the effectiveness and safety of ixazomib-lenalidomide-dexamethasone in routine clinical practice.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
Roman Hájek , Jiří Minařík, Jan Straub et al.
Future Oncology 17(19) (2021) doi/10.2217/fon-2020-1225
Roman Hájek is Professor of Oncology, Head of the Department of Haematooncology in the University Hospital Ostrava (Czech Republic) and Vice-Rector for Strategy and Development at the University of Ostrava. After qualifying in medicine in 1988 from JE Purkyne /Masaryk/ University Faculty of Medicine Brno (Czechia), Prof Hájek received a PhD in haematology in 1995 and completed degrees in Internal Medicine in 1996, in Medical Oncology in 1998 and in Hematology in 2011.
Prof Hájek is also Head of the Blood Cancer Research Group (BCRG) – international research team, joint project of the Medical Faculty, University of Ostrava and the Hematooncology Department, University Hospital Ostrava with a number of national and international collaborations.
Prof Hájek is chairman and a founding member of the Czech Myeloma Group. RMG Registry of Monoclonal Gammopathy of CMG is one of the largest registry focused on monoclonal gammopathies in the world. Prof Hájek has published over 500 scientific articles (h-index: 47) and book chapters and is an editor of the European Journal of Hematology. His research interests include multiple myeloma and other monoclonal gammopathies, bone marrow transplantation, and immunotherapy.